Epiregulin as a marker for the initial steps of ovarian cancer development

  • Authors:
    • Abraham Amsterdam
    • Elias Shezen
    • Calanit Raanan
    • Yasmin Slilat
    • Alon Ben-Arie
    • Diana Prus
    • Letizia Schreiber
  • View Affiliations

  • Published online on: July 14, 2011     https://doi.org/10.3892/ijo.2011.1123
  • Pages: 1165-1172
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epiregulin (Ep) was found to be produced in non-cancer ovarian cells in response to gonadotropin stimulation as well in ovarian cancer cells in an autonomous manner. However, there were no systematic follow-up studies of Ep expression in the development of different stages of ovarian cancer. Using specific antibodies to Ep and the indirect immunocytochemistry methods, we found that in normal ovary the staining for Ep was mainly confined to the epithelial cells, while the stromal cells were only occasionally and moderately stained. In contrast in benign serous and mucinous tumors most of the tumor cells showed a clear staining in the cytoplasm. In borderline serous and mucinous tumors the staining was much more intensive, and appear occasionally in aggregated form. In serous, mucinous and endometrioid carcinomas labeling remain high, with more frequent aggregated form. It is suggested that follow-up of the expression of Ep can serve as a reliable early indication of the development of ovarian cancer. Moreover, the cytoplasmic aggregation of Ep may suggest a specific mechanism of the release of this growth factor to the extracellular space in order to exert its autocrine and paracrine effect on the family of the EGF receptors.

Related Articles

Journal Cover

November 2011
Volume 39 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Amsterdam, A., Shezen, E., Raanan, C., Slilat, Y., Ben-Arie, A., Prus, D., & Schreiber, L. (2011). Epiregulin as a marker for the initial steps of ovarian cancer development. International Journal of Oncology, 39, 1165-1172. https://doi.org/10.3892/ijo.2011.1123
MLA
Amsterdam, A., Shezen, E., Raanan, C., Slilat, Y., Ben-Arie, A., Prus, D., Schreiber, L."Epiregulin as a marker for the initial steps of ovarian cancer development". International Journal of Oncology 39.5 (2011): 1165-1172.
Chicago
Amsterdam, A., Shezen, E., Raanan, C., Slilat, Y., Ben-Arie, A., Prus, D., Schreiber, L."Epiregulin as a marker for the initial steps of ovarian cancer development". International Journal of Oncology 39, no. 5 (2011): 1165-1172. https://doi.org/10.3892/ijo.2011.1123